Premium
Histone deacetylase inhibitor sodium butyrate promotes the osteogenic differentiation of rat adipose‐derived stem cells
Author(s) -
Hu Xiaoqing,
Fu Yutuo,
Zhang Xin,
Dai Linghui,
Zhu Jingxian,
Bi Zhenggang,
Ao Yingfang,
Zhou Chunyan
Publication year - 2014
Publication title -
development, growth and differentiation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 66
eISSN - 1440-169X
pISSN - 0012-1592
DOI - 10.1111/dgd.12119
Subject(s) - sodium butyrate , biology , adipose tissue , histone deacetylase inhibitor , histone deacetylase , microbiology and biotechnology , butyrate , stem cell , histone , pharmacology , cancer research , endocrinology , biochemistry , gene , fermentation
Adult stem cells hold great promise for use in tissue repair and regeneration. Recently, adipose tissue‐derived stem cells ( ADSC s) were found to be an appealing alternative to bone marrow stem cells ( BMSC s) for bone tissue engineering. The main benefit of ADSC s is that they can be easily and abundantly available from adipose tissue. However, our prior study discovered an important phenomenon that BMSC s have greater osteogenic potential than ADSC s in vitro and epigenetic regulation plays a critical role in runt‐related transcription factor 2 (Runx2) expression and thus osteogenesis. In this study, we aimed to improve the osteogenic potential of ADSC s by histone deacetylase inhibitor sodium butyrate (NaBu). We found that NaBu promoted rat ADSC osteogenic differentiation by altering the epigenetic modifications on the Runx2 promoter.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom